Clinical Trial Update: Study of BGG492 in Patients With Chronic Subjective Tinnitus [Phase 2]

View source ↗

Summary

Phase 2 study of BGG492 for chronic subjective tinnitus has completed; the update notes the trial status as COMPLETED but does not provide efficacy results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tinnitus

Drugs mentioned

• BGG492

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Subjective Tinnitus | Phase 2 | Status: COMPLETED